Subsequent in vivo experiments showed that TRP-1 CD4+ T cells were able to eradicate established MHC-II-deficient, but not TRP-1-deficient HCmel12 melanomas (Fig. 1l,m and Extended Data Fig. 2n–p). This evidence concerns the gene CD4 and melanoma.